Pacira BioSciences, Inc. PCRX
Pacira BioSciences, Inc. (Nasdaq: PCRX) is a pain/anesthesia drug developer. Its lead program, EXPAREL, is in Phase 2 for local and regional analgesia (post-operative pain). Its next catalyst on record is ZILRETTA (shoulder OA): Phase 3 registration study topline results (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ZILRETTA (shoulder OA) — Phase 3 registration study topline results (2026). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| EXPAREL | local analgesia via infiltration (ages 6+) and regional analgesia (brachial plexus, sciatic, adductor canal blocks in adults) | small molecule | Approved |
| ZILRETTA | osteoarthritis knee pain | small molecule | Approved |
| PCRX-201 (enekinragene inzadenovec) | moderate to severe knee osteoarthritis | gene therapy | Phase 2 |
| PCRX-2002 | bunionectomy (post-operative pain) | small molecule | Phase 2 |
| PCRX-1001 | canine osteoarthritis | gene therapy | Pre-clinical |
| PCRX-1002 | Dry Eye Disease | gene therapy | Pre-clinical |
| PCRX-1003 | Degenerative Disc Disease | gene therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 pain/anesthesia companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.